 
MAINE STATE LEGISLATURE  
 
 
 
The following document is provided by the 
LAW AND LEGISLATIVE DIGITAL LIBRARY  
at the Maine State Law and Legislative Reference Library 
http://legislature.m aine.gov/lawlib 
 
 
 
 
 
 
 
 
 
 
Reproduced from electronic originals 
(may include minor formatting diffe rences from printed original) 
 
 
Printed on recycled paper131st MAINE LEGISLATURE
FIRST SPECIAL SESSION-2023
Legislative Document No. 1577
H.P. 1022 House of Representatives, April 11, 2023
An Act to Require Health Insurance Coverage for Biomarker 
Testing
Reference to the Committee on Health Coverage, Insurance and Financial Services 
suggested and ordered printed.
ROBERT B. HUNT
Clerk
Presented by Representative ZAGER of Portland.
Cosponsored by Senator BENNETT of Oxford and
Representatives: ARATA of New Gloucester, CYRWAY of Albion, JAVNER of Chester, 
PERRY of Calais, SWALLOW of Houlton, Senators: BAILEY of York, RENY of Lincoln.

Page 1 - 131LR0655(01)1Be it enacted by the People of the State of Maine as follows:
2Sec. 1.  22 MRSA §3174-KKK is enacted to read:
3§3174-KKK.  Biomarker testing coverage
41. Definitions.  As used in this section, unless the context otherwise indicates, the 
5 following terms have the following meanings.
6 A. "Biomarker" means a characteristic that is objectively measured and evaluated as 
7 an indicator of a normal biological process, pathogenic process or pharmacologic 
8 response to a specific therapeutic intervention, including a known gene-drug 
9 interaction for a medication being considered for use or already being administered. 
10 "Biomarker" includes but is not limited to a gene mutation, characteristic of a gene or 
11 protein expression.
12 B. "Biomarker testing" means the analysis of a patient's tissue, blood or other biological 
13 specimen for the presence of a biomarker.  "Biomarker testing" includes but is not 
14 limited to a single analyte test, multiplex panel test, protein expression and whole 
15 exome, whole genome and whole transcriptome sequencing.
16 C. "Consensus statement" means a statement:
17 (1) Developed by an independent, multidisciplinary panel of experts using a 
18 transparent methodology and reporting structure and with a conflict of interest 
19 policy;
20 (2) Aimed at specific clinical circumstances; and
21 (3) Based on the best available evidence for the purpose of optimizing the 
22 outcomes of clinical care.
23 D. "Nationally recognized clinical practice guideline" means an evidence-based 
24 clinical practice guideline developed by an independent organization or medical 
25 professional society using a transparent methodology and reporting structure and with 
26 a conflict of interest policy that establishes a standard of care informed by a systematic 
27 review of evidence and an assessment of the benefits and risks of alternative care 
28 options and includes recommendations intended to optimize patient care. 
292. Required coverage.  The department shall provide coverage for biomarker testing 
30 for the purposes of diagnosis, treatment, appropriate management or ongoing monitoring 
31 of a disease or condition of a MaineCare member when the test is supported by medical 
32 and scientific evidence, including, but not limited to:
33 A.  A labeled indication for a test approved or cleared by the federal Food and Drug 
34 Administration; 
35 B.  An indicated test for a drug approved by the federal Food and Drug Administration; 
36 C.  A warning or precaution on a label of a drug approved by the federal Food and 
37 Drug Administration;
38 D.  A federal Department of Health and Human Services, Centers for Medicare and 
39 Medicaid Services national coverage determination or Medicare administrative 
40 contractor local coverage determination; or
41 E.  A nationally recognized clinical practice guideline or consensus statement.
Page 2 - 131LR0655(01)1 Coverage described in this subsection must provide for the delivery of biomarker testing 
2 services in a manner that limits disruptions in care, including the need for multiple biopsies 
3 or biological specimen samples.
4Sec. 2.  24 MRSA §2320-H is enacted to read:
5§2320-H.  Biomarker testing insurance coverage
61. Definitions.  As used in this section, unless the context otherwise indicates, the 
7 following terms have the following meanings.
8 A. "Biomarker" means a characteristic that is objectively measured and evaluated as 
9 an indicator of a normal biological process, pathogenic process or pharmacologic 
10 response to a specific therapeutic intervention, including a known gene-drug 
11 interaction for a medication being considered for use or already being administered. 
12 "Biomarker" includes but is not limited to a gene mutation, characteristic of a gene or 
13 protein expression.
14 B. "Biomarker testing" means the analysis of a patient's tissue, blood or other biological 
15 specimen for the presence of a biomarker.  "Biomarker testing" includes but is not 
16 limited to a single analyte test, multiplex panel test, protein expression and whole 
17 exome, whole genome and whole transcriptome sequencing.
18 C. "Consensus statement" means a statement:
19 (1) Developed by an independent, multidisciplinary panel of experts using a 
20 transparent methodology and reporting structure and with a conflict of interest 
21 policy;
22 (2) Aimed at specific clinical circumstances; and
23 (3) Based on the best available evidence for the purpose of optimizing the 
24 outcomes of clinical care.
25 D. "Nationally recognized clinical practice guideline" means an evidence-based 
26 clinical practice guideline developed by an independent organization or medical 
27 professional society using a transparent methodology and reporting structure and with 
28 a conflict of interest policy that establishes a standard of care informed by a systematic 
29 review of evidence and an assessment of the benefits and risks of alternative care 
30 options and includes recommendations intended to optimize patient care. 
312. Required coverage.  An individual and group nonprofit hospital and medical 
32 services plan contract must provide coverage for biomarker testing for the purposes of 
33 diagnosis, treatment, appropriate management or ongoing monitoring of a disease or 
34 condition of a subscriber or member when the test is supported by medical and scientific 
35 evidence, including, but not limited to:
36 A.  A labeled indication for a test approved or cleared by the federal Food and Drug 
37 Administration; 
38 B.  An indicated test for a drug approved by the federal Food and Drug Administration; 
39 C.  A warning or precaution on a label of a drug approved by the federal Food and 
40 Drug Administration;
Page 3 - 131LR0655(01)1 D.  A federal Department of Health and Human Services, Centers for Medicare and 
2 Medicaid Services national coverage determination or Medicare administrative 
3 contractor local coverage determination; or
4 E.  A nationally recognized clinical practice guideline or consensus statement.
5 A contract described in this subsection must provide for coverage in a manner that limits 
6 disruptions in care, including the need for multiple biopsies or biological specimen 
7 samples.
83. Utilization review.  If an individual and group nonprofit hospital and medical 
9 services plan contract contains a provision whereby in nonemergency cases the insured is 
10 required to be prospectively evaluated through a prehospital admission certification, a 
11 preinpatient service eligibility program or any similar preutilization review or screening 
12 procedure prior to biomarker testing, the utilization review entity or any 3rd party acting 
13 on behalf of an organization or entity subject to this section must approve or deny a prior 
14 authorization request and notify the subscriber or member, the subscriber's or member's 
15 health care provider and any entity requesting authorization of the service within 72 hours 
16 for nonurgent requests or within 24 hours for urgent requests.
174. Application.  This section applies to a policy, contract and certificate, except those 
18 designed to cover only specific diseases, accidental injury or dental procedures, executed, 
19 delivered, issued for delivery, continued or renewed in this State. For purposes of this 
20 section, a contract is deemed to be renewed no later than the next yearly anniversary of the 
21 contract date.  
22Sec. 3.  24-A MRSA §2745-H is enacted to read:
23§2745-H.  Biomarker testing insurance coverage
241. Definitions.  As used in this section, unless the context otherwise indicates, the 
25 following terms have the following meanings.
26 A.  "Biomarker" means a characteristic that is objectively measured and evaluated as 
27 an indicator of a normal biological process, pathogenic process or pharmacologic 
28 response to a specific therapeutic intervention, including a known gene-drug 
29 interaction for a medication being considered for use or already being administered. 
30 "Biomarker" includes but is not limited to a gene mutation, characteristic of a gene or 
31 protein expression.
32 B.  "Biomarker testing" means the analysis of a patient's tissue, blood or other 
33 biological specimen for the presence of a biomarker.  "Biomarker testing" includes but 
34 is not limited to a single analyte test, multiplex panel test, protein expression and whole 
35 exome, whole genome and whole transcriptome sequencing.
36 C. "Consensus statement" means a statement:
37 (1) Developed by an independent, multidisciplinary panel of experts using a 
38 transparent methodology and reporting structure and with a conflict of interest 
39 policy;
40 (2) Aimed at specific clinical circumstances; and
41 (3) Based on the best available evidence for the purpose of optimizing the 
42 outcomes of clinical care.
Page 4 - 131LR0655(01)1 D. "Nationally recognized clinical practice guideline" means an evidence-based 
2 clinical practice guideline developed by an independent organization or medical 
3 professional society using a transparent methodology and reporting structure and with 
4 a conflict of interest policy that establishes a standard of care informed by a systematic 
5 review of evidence and an assessment of the benefits and risks of alternative care 
6 options and includes recommendations intended to optimize patient care. 
72. Required coverage.  An individual insurance policy, except those designed to cover 
8 only specific diseases, accidental injury or dental procedures, must provide coverage for 
9 biomarker testing for the purposes of diagnosis, treatment, appropriate management or 
10 ongoing monitoring of a disease or condition of a person covered by the policy when the 
11 test is supported by medical and scientific evidence, including, but not limited to:
12 A.  A labeled indication for a test approved or cleared by the federal Food and Drug 
13 Administration; 
14 B.  An indicated test for a drug approved by the federal Food and Drug Administration; 
15 C.  A warning or precaution on a label of a drug approved by the federal Food and 
16 Drug Administration;
17 D.  A federal Department of Health and Human Services, Centers for Medicare and 
18 Medicaid Services national coverage determination or Medicare administrative 
19 contractor local coverage determination; or
20 E.  A nationally recognized clinical practice guideline or consensus statement.
21 A policy described in this subsection must provide for coverage in a manner that limits 
22 disruptions in care, including the need for multiple biopsies or biological specimen 
23 samples.
243. Utilization review.  If an individual insurance policy contains a provision whereby 
25 in nonemergency cases the insured is required to be prospectively evaluated through a 
26 prehospital admission certification, a preinpatient service eligibility program or any similar 
27 preutilization review or screening procedure prior to biomarker testing, the utilization 
28 review entity or any 3rd party acting on behalf of an organization or entity subject to this 
29 section must approve or deny a prior authorization request and notify the person covered 
30 by the policy, the person's health care provider and any entity requesting authorization of 
31 the service within 72 hours for nonurgent requests or within 24 hours for urgent requests.
324. Application.  This section applies to a policy, contract and certificate executed, 
33 delivered, issued for delivery, continued or renewed in this State. For purposes of this 
34 section, a contract is deemed to be renewed no later than the next yearly anniversary of the 
35 contract date.  
36Sec. 4.  24-A MRSA §2837-I is enacted to read:
37§2837-I.  Biomarker testing insurance coverage
381. Definitions.  As used in this section, unless the context otherwise indicates, the 
39 following terms have the following meanings.
40 A. "Biomarker" means a characteristic that is objectively measured and evaluated as 
41 an indicator of a normal biological process, pathogenic process or pharmacologic 
42 response to a specific therapeutic intervention, including a known gene-drug 
Page 5 - 131LR0655(01)43 interaction for a medication being considered for use or already being administered. 
44 "Biomarker" includes but is not limited to a gene mutation, characteristic of a gene or 
45 protein expression.
4 B. "Biomarker testing" means the analysis of a patient's tissue, blood or other biological 
5 specimen for the presence of a biomarker.  "Biomarker testing" includes but is not 
6 limited to a single analyte test, multiplex panel test, protein expression and whole 
7 exome, whole genome and whole transcriptome sequencing.
8 C. "Consensus statement" means a statement:
9 (1) Developed by an independent, multidisciplinary panel of experts using a 
10 transparent methodology and reporting structure and with a conflict of interest 
11 policy;
12 (2) Aimed at specific clinical circumstances; and
13 (3) Based on the best available evidence for the purpose of optimizing the 
14 outcomes of clinical care.
15 D. "Nationally recognized clinical practice guideline" means an evidence-based 
16 clinical practice guideline developed by an independent organization or medical 
17 professional society using a transparent methodology and reporting structure and with 
18 a conflict of interest policy that establishes a standard of care informed by a systematic 
19 review of evidence and an assessment of the benefits and risks of alternative care 
20 options and includes recommendations intended to optimize patient care. 
212. Required coverage.  A group insurance policy, except those designed to cover only 
22 specific diseases, accidental injury or dental procedures, must provide coverage for 
23 biomarker testing for the purposes of diagnosis, treatment, appropriate management or 
24 ongoing monitoring of a disease or condition of an insured person or subscriber covered by 
25 that policy when the test is supported by medical and scientific evidence, including, but not 
26 limited to:
27 A.  A labeled indication for a test approved or cleared by the federal Food and Drug 
28 Administration; 
29 B.  An indicated test for a drug approved by the federal Food and Drug Administration; 
30 C.  A warning or precaution on a label of a drug approved by the federal Food and 
31 Drug Administration;
32 D.  A federal Department of Health and Human Services, Centers for Medicare and 
33 Medicaid Services national coverage determination or Medicare administrative 
34 contractor local coverage determination; or
35 E.  A nationally recognized clinical practice guideline or consensus statement.
36 A policy described in this subsection must provide for coverage in a manner that limits 
37 disruptions in care, including the need for multiple biopsies or biological specimen 
38 samples.
393. Utilization review.  If a group insurance policy contains a provision whereby in 
40 nonemergency cases the insured is required to be prospectively evaluated through a 
41 prehospital admission certification, a preinpatient service eligibility program or any similar 
42 preutilization review or screening procedure prior to biomarker testing, the utilization 1
2
3
Page 6 - 131LR0655(01)43 review entity or any 3rd party acting on behalf of an organization or entity subject to this 
44 section must approve or deny a prior authorization request and notify the insured person or 
45 subscriber covered by that policy, the insured person's or subscriber's health care provider 
46 and any entity requesting authorization of the service within 72 hours for nonurgent 
47 requests or within 24 hours for urgent requests.
64. Application.  This section applies to a policy, contract and certificate executed, 
7 delivered, issued for delivery, continued or renewed in this State. For purposes of this 
8 section, a contract is deemed to be renewed no later than the next yearly anniversary of the 
9 contract date.  
10Sec. 5.  24-A MRSA §4237-B is enacted to read:
11§4237-B.  Biomarker testing insurance coverage
121. Definitions.  As used in this section, unless the context otherwise indicates, the 
13 following terms have the following meanings.
14 A. "Biomarker" means a characteristic that is objectively measured and evaluated as 
15 an indicator of a normal biological process, pathogenic process or pharmacologic 
16 response to a specific therapeutic intervention, including a known gene-drug 
17 interaction for a medication being considered for use or already being administered. 
18 "Biomarker" includes but is not limited to a gene mutation, characteristic of a gene or 
19 protein expression.
20 B. "Biomarker testing" means the analysis of a patient's tissue, blood or other biological 
21 specimen for the presence of a biomarker.  "Biomarker testing" includes but is not 
22 limited to a single analyte test, multiplex panel test, protein expression and whole 
23 exome, whole genome and whole transcriptome sequencing.
24 C. "Consensus statement" means a statement:
25 (1) Developed by an independent, multidisciplinary panel of experts using a 
26 transparent methodology and reporting structure and with a conflict of interest 
27 policy;
28 (2) Aimed at specific clinical circumstances; and
29 (3) Based on the best available evidence for the purpose of optimizing the 
30 outcomes of clinical care.
31 D. "Nationally recognized clinical practice guideline" means an evidence-based 
32 clinical practice guideline developed by an independent organization or medical 
33 professional society using a transparent methodology and reporting structure and with 
34 a conflict of interest policy that establishes a standard of care informed by a systematic 
35 review of evidence and an assessment of the benefits and risks of alternative care 
36 options and includes recommendations intended to optimize patient care. 
372. Required coverage.  Individual or group coverage subject to this chapter must 
38 provide coverage for biomarker testing for the purposes of diagnosis, treatment, appropriate 
39 management or ongoing monitoring of a disease or condition of an insured person, member 
40 or subscriber covered by that policy when the test is supported by medical and scientific 
41 evidence, including, but not limited to:1
2
3
4
5
Page 7 - 131LR0655(01)1 A.  A labeled indication for a test approved or cleared by the federal Food and Drug 
2 Administration; 
3 B.  An indicated test for a drug approved by the federal Food and Drug Administration; 
4 C.  A warning or precaution on a label of a drug approved by the federal Food and 
5 Drug Administration;
6 D.  A federal Department of Health and Human Services, Centers for Medicare and 
7 Medicaid Services national coverage determination or Medicare administrative 
8 contractor local coverage determination; or
9 E.  A nationally recognized clinical practice guideline or consensus statement.
10 A policy described in this subsection must provide for coverage in a manner that limits 
11 disruptions in care, including the need for multiple biopsies or biological specimen 
12 samples.
133. Utilization review.  If a group insurance policy contains a provision whereby in 
14 nonemergency cases the insured is required to be prospectively evaluated through a 
15 prehospital admission certification, a preinpatient service eligibility program or any similar 
16 preutilization review or screening procedure prior to biomarker testing, the utilization 
17 review entity or any 3rd party acting on behalf of an organization or entity subject to this 
18 section must approve or deny a prior authorization request and notify the insured person or 
19 subscriber covered by that policy, the insured person's, member's or subscriber's health care 
20 provider and any entity requesting authorization of the service within 72 hours for 
21 nonurgent requests or within 24 hours for urgent requests.
224. Application.  This section applies to a policy, contract and certificate, except those 
23 designed to cover only specific diseases, accidental injury or dental procedures, executed, 
24 delivered, issued for delivery, continued or renewed in this State. For purposes of this 
25 section, a contract is deemed to be renewed no later than the next yearly anniversary of the 
26 contract date.  
27Sec. 6.  Application.  The requirements of the Maine Revised Statutes, Title 22, 
28 section 3174-KKK, Title 24, section 2320-H and Title 24-A, sections 2745-H, 2837-I and 
29 4237-B apply to a policy, contract, certificate or other instrument of insurance coverage 
30 that takes effect or is renewed on or after the effective date of this Act.
31SUMMARY
32 This bill requires insurance coverage, including coverage in the MaineCare program, 
33 for biomarker testing.32
33
